Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AtCor Medical, the developer and marketer of the SphygmoCor system which measures central blood pressures and arterial stiffness non-invasively, has signed a new agreement to supply SphygmoCor systems and clinical trial support services to an international pharmaceutical company.
Subscribe to our email newsletter
The minimum total value of this contract is $930,000, the majority of which will be recognized in the current financial year. This new order brings the minimum total value of pharmaceutical trial contracts secured by AtCor in the past 130 days to over $3.7 million.
According to the company, the SphygmoCor system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring.
Duncan Ross, CEO of AtCor Medical, said: “We continue to execute on our strategy in pursuing the pharmaceutical clinical trials market. This new contract is not only evidence of the increasing importance of SphygmoCor as a tool for understanding drug efficacy and mechanisms of action in pharmaceutical clinical trials but also reinforces its emerging importance as a drug therapy management tool in clinical practice. We look forward to continuing to build mutually beneficial relationships with our growing list of pharmaceutical trial customers.”